AptarGroup, Inc. (ATR) Stock Price
ATRStock
$124.51−3.60%52W
Market Cap$7.92B
P/E20.15x
PEG Ratio2.59
Div yield1.28%
Beta0.35
ATR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-14.87%
Price vs S&P 500 (4W)2.22%
PEG Ratio2.59
VGM Score51.60
P/E Ratio (Annual)20.15x
Indicated Dividend Yield (Annual)1.28%
ATR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.35 | $1.42 | +4.85%(+$0.07) | |
| Q1 2026 | $1.15 | $1.19 | +3.48%(+$0.04) | |
| Q4 2025 | $1.23 | $1.25 | +1.74%(+$0.02) | |
| Q3 2025 | $1.57 | $1.62 | +3.08%(+$0.05) | |
| Q2 2025 | $1.59 | $1.66 | +4.67%(+$0.07) |
ATR Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.08
4.08
4.25
4.25
Industry Peers — Plastics Products(9)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
ATRAptarGroup, Inc. | C | C | B | 20.2x | 13.6% | 5.2% | 1.3% | $124.51 |
| ENTGEntegris Inc | F | C | B | 90.0x | 7.6% | 11.4% | 0.4% | $138.74 |
| AWIArmstrong World Industries, Inc. | D | B | B | 23.0x | 35.4% | 11.6% | 1.3% | $168.16 |
| NWLNewell Brands Inc. | B | D | B | — | -8.9% | -5.2% | 3.7% | $5.65 |
| MYEMyers Industries, Inc. | A | D | A | 33.7x | 41.4% | -22.1% | 3.1% | $31.30 |
| KRTKarat Packaging Inc. Common Stock | D | B | A | 33.8x | 32.5% | 9.6% | 3.7% | $53.31 |
| SWIMLatham Group, Inc. Common Stock | C | C | C | 64.7x | 1.3% | 6.2% | — | $6.12 |
| CMTCore Molding Technologies, Inc. | C | F | C | 18.1x | 4.6% | 4.3% | — | $22.91 |
| DSWLDeswell Industries Inc | A | D | D | 4.6x | 9.8% | -1.1% | 7.4% | $3.11 |
| NCLNorthann Corp. | B | C | F | — | -141.8% | 0.8% | — | $0.00 |
About AptarGroup, Inc.
AptarGroup is a global leader in dispensing systems and packaging for consumer goods and pharmaceuticals, generating nearly half its revenue from Europe and 28% from the United States. The company operates three segments—Pharma, Beauty, and Closures—with the Pharma segment generating over two-thirds of group profits. This profit concentration underscores the strategic importance of its pharmaceutical business.